Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunotech Biopharm Ltd ( (HK:6978) ) just unveiled an announcement.
Immunotech Biopharm Ltd has announced that it is preparing to submit an application for conditional approval of its core product candidate, EAL®, to the Center for Drug Evaluation of the National Medical Products Administration in China. EAL® is a multi-target cellular immunotherapy product used in cancer treatment, and the company has completed Phase II clinical trials with 430 patients. The submission will be subject to rigorous evaluation, and there is no guarantee of approval, but this step represents a significant development in the company’s efforts to bring EAL® to market.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a leading cellular immunotherapy biopharmaceutical company in China, focusing on the research, development, and commercialization of T cell immunotherapy. Established in 2006, the company specializes in cellular immunotherapy drugs for cancers and other major diseases, utilizing advanced theories in immunology, cell biology, and genetics. Its product pipeline includes non-genetically-modified and genetically-modified products, featuring multi-target and single-target therapies.
YTD Price Performance: 96.52%
Average Trading Volume: 613,965
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$2.33B
See more insights into 6978 stock on TipRanks’ Stock Analysis page.